ArticleVeterinary medicine (Auckland, N.Z.)2025
Serum Onconeural Antibodies in Dogs and Cats for Early Diagnosis of Cancer.
Article in Veterinary medicine (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the leading causes of death in dogs and cats worldwide, and effective early detection techniques and reliable therapies are still lacking. Given the high demand for early cancer detection and differentiation in veterinary diagnostics, we developed and validated a new diagnostic approach to assess onconeural antibodies, also known as high-risk antibodies, in dog and cat blood serum samples. We determined the presence of systemic onconeural/high-risk (ONHR) antibodies, their suitability for early cancer diagnostics, and the feasibility of differentiating various malignancies. Our results identified several ONHR antibodies in 0.1 mL of specimens by the immunoblot-based technique, which was confirmed by indirect immunofluorescence assay. The diagnostic performance for detecting identified antibodies has demonstrated >95% sensitivity in dogs, >93% sensitivity in cats, as well as >97% specificity in dogs, and >95% specificity in cats. Thus, our data provide the first proof-of-principle that onconeural antibodies can be detected in dogs and cats, and their identification in serum might serve as a new tool for early cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.